November 3, 2023 07:28 AM EDTUpdated 09:10 AM

Novartis’ Pluvicto supply ‘fully unconstrained,’ eyes manufacturing expansion

Anna Brown

News Reporter

Novartis says that access to Pluvicto is now “fully unconstrained” as the pharma giant plans for manufacturing expansions to ensure a steady supply of the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Novartis’ Pluvicto supply ‘fully unconstrained,’ eyes manufacturing expansion

Anna Brown

News Reporter

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Icon's quarterly earnings hit by biotech and pharma pullback

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

No­var­tis’ Plu­vic­to sup­ply ‘ful­ly un­con­strained,’ eyes man­u­fac­tur­ing ex­pan­sion

News Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Novartis’ Pluvicto supply ‘fully unconstrained,’ eyes manufacturing expansion